Acutaas Chemicals Q1 FY27 Results: Revenue Climbs 59%

Q1 FY27 performance at a glance

Acutaas Chemicals Ltd reported revenue from operations of ₹329.67 crore in the quarter ended June 2026, marking year-on-year growth of 59.08%. The company’s net profit, reported as profit and loss for the year in the quarterly data, rose to ₹74.99 crore from ₹44.01 crore in the corresponding quarter a year earlier. The June quarter figures indicate stronger annual growth across revenue and profitability, although revenue declined sequentially from the March 2026 quarter. The company has scheduled its next board meeting for October 27, 2026, to consider unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

Revenue rises from the June 2025 base

Revenue from operations stood at ₹329.67 crore in Q1 FY27, compared with ₹207.24 crore in Q1 FY26. This represented an increase of ₹122.43 crore over the year-earlier period. Acutaas Chemicals said the quarterly performance was supported by Advanced Pharmaceutical Intermediates, where revenue rose 76.5%. Total income for the June 2026 quarter was ₹331.48 crore, compared with ₹223.17 crore in June 2025. The difference between total income and revenue from operations reflects other income reported in the quarterly statement.

The company’s revenue was lower than ₹432.75 crore reported in the preceding March 2026 quarter. On a quarter-on-quarter basis, revenue from operations declined 23.82%. The March quarter was the highest revenue quarter among the five quarters presented in the data. Revenue had moved from ₹207.24 crore in June 2025 to ₹306.20 crore in September 2025, ₹393.18 crore in December 2025, and ₹432.75 crore in March 2026 before moderating in June 2026.

Profit grows faster than revenue

Profit for the June 2026 quarter increased 70.4% year-on-year to ₹74.99 crore, from ₹44.01 crore in June 2025. The reported PAT figure was about ₹74.9 crore in the company’s quarterly highlights. This growth exceeded the 59.1% rise in revenue from operations, indicating a stronger profit outcome compared with the year-earlier quarter. However, profit was below ₹134.28 crore reported in the March 2026 quarter.

Operating profit was ₹113.07 crore in Q1 FY27, more than double ₹50.91 crore reported in Q1 FY26. EBITDA rose to ₹114.87 crore from ₹66.84 crore a year earlier. The company’s reported EBITDA margin was 34.3% for the June 2026 quarter. EBIT stood at ₹105.05 crore, compared with ₹58.71 crore in the corresponding quarter of the previous year.

Key quarterly financial figures

Sequential comparison shows lower June-quarter revenue

The Q1 FY27 result followed a stronger March 2026 quarter, when revenue from operations was ₹432.75 crore and EBITDA was ₹194.62 crore. Total income also declined sequentially, falling from ₹443.86 crore in March 2026 to ₹331.48 crore in June 2026. Operating profit declined from ₹183.51 crore in the March quarter to ₹113.07 crore in the June quarter. Net profit moved from ₹134.28 crore to ₹74.99 crore over the same period.

The year-on-year comparison remains favourable because the June 2025 base was lower across the main financial measures. In Q1 FY26, EBITDA was ₹66.84 crore and operating profit was ₹50.91 crore. Acutaas Chemicals’ reported June 2026 results therefore show both a higher revenue base and improved profitability from the corresponding quarter last year. The available data does not provide a detailed cost breakup or management guidance for future quarters.

Recent quarterly trend

Acutaas Chemicals’ revenue trend shows growth from ₹172 crore in September 2023 to ₹330 crore in June 2026, based on the quarterly series provided. Revenue reached ₹308 crore in March 2025 before declining to ₹207 crore in June 2025. It subsequently increased to ₹306 crore in September 2025, ₹393 crore in December 2025 and ₹433 crore in March 2026. The June 2026 revenue of about ₹330 crore remained above the June 2025 level.

The company had earlier reported Q2 FY26 revenue of ₹306.20 crore, EBITDA of ₹95.30 crore and profit of ₹71.90 crore. Those results had represented year-on-year growth of 24.1% in revenue, 94.8% in EBITDA and 91.3% in PAT. The June 2026 figures extend the pattern of higher year-on-year earnings reported in the available quarterly information.

Board meeting scheduled for Q2 FY27 results

Acutaas Chemicals has informed BSE that its board meeting is scheduled for October 27, 2026. The board is expected to consider and approve unaudited standalone and consolidated results for Q2 FY27 and the half year ended September 30, 2026. The Q2 FY27 reporting period covers July 1, 2026 to September 30, 2026. The comparable Q2 FY26 base included revenue of ₹306.20 crore and profit of ₹71.86 crore.

Equirus Securities has also organised an earnings conference call at 4 pm IST on October 27, 2026, to discuss the Q2 and H1 FY27 financial results. The call is expected to include company management, including Chairman Naresh Patel and CFO Bhavin Shah, according to the information provided. Investors and analysts will be able to assess the Q2 financial disclosure and management commentary when the results are considered by the board.

What the result means for investors

The Q1 FY27 numbers show that Acutaas Chemicals delivered substantial year-on-year increases in revenue, EBITDA and net profit. The 76.5% growth cited for Advanced Pharmaceutical Intermediates was identified as a key contributor to revenue performance. At the same time, the sequential decline from the March 2026 quarter is visible across revenue, operating profit, EBITDA and net profit. Both comparisons are relevant because the March quarter represents the immediate reporting base, while June 2025 provides the annual base.

The October 27 board meeting is the next confirmed event for shareholders tracking the company’s financial performance. The Q2 result will provide the next set of reported figures for revenue, profit and operating performance. Until the board considers the results, the available confirmed financial information remains the Q1 FY27 performance filed on July 24, 2026.

Conclusion

Acutaas Chemicals reported Q1 FY27 revenue of ₹329.67 crore, up 59.08% year-on-year, while net profit rose 70.4% to ₹74.99 crore. EBITDA reached ₹114.87 crore, supported by growth in Advanced Pharmaceutical Intermediates. The company’s board meeting and earnings call on October 27, 2026 are the next scheduled updates for the Q2 FY27 and H1 FY27 financial performance.